statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 PR Newswire WASHINGTON...

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA...

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ ANDA Litigation

'Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact.'
read more...

US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share...

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share

Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak...

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan PR Newswire WASHINGTON, April 17, 2024 WASHINGTON, April...

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak PR Newswire...

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

StockNews.com downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) from a buy rating to a hold rating in a research report released on Saturday morning.
Separately, TheStreet...

Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by StockNews.com to "Hold"

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much...

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the...

Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Volume	662,974.00
52-Wk High	$7.00
52-Wk Low	$3.30

Period	Estimated	Reported	Surprise	Result
Q1'24	$0.05	--	--	N/A
Q4'23	-$0.09	-$0.04	55.56%	BEAT
Q3'23	-$0.04	$0.00	100.00%	BEAT
Q2'23	-$0.13	$0.03	123.08%	BEAT
Q1'23	--	$0.06	--	N/A

VNDA Vanda Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals